Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice … 300 mg alone or allopurinol 300 mg followed by febuxostat 80 mg/120 mg. The proportion of patients achieving the target … incremental cost-effectiveness ratio (ICER). Second-line therapy with febuxostat 80 mg/120 mg versus with allopurinol alone …

, the manufacturer of febuxostat (Adenuric; Ipsen, UK) was invited to submit evidence for the clinical and cost … effectiveness of febuxostat for the management of hyperuricaemia in patients with gout. The School of Health and Related Research …, multi-arm, randomized, double blind, controlled trials comparing the efficacy and safety of febuxostat with fixed …